Company news
Shanghai Junshi Biosciences Co., Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
(688180)"Shanghai Junshi Biosciences Co., Ltd."Report for Q3 2026
October 29, 2026
(688180)"Shanghai Junshi Biosciences Co., Ltd."Announcement on Voluntary Disclosure of Completion of First Patient Dosing in the Phase III Clinical Trial of JS207 in Combination with JS007 for First-Line Treatment of Advanced Hepatocellular Carcinoma
October 29, 2026
(688180)"Shanghai Junshi Biosciences Co., Ltd."Announcement on Use of Temporarily Idle Raised Funds for Cash Management
October 29, 2026
(688180)"Shanghai Junshi Biosciences Co., Ltd."Announcement on Convening the Q3 2026 Performance Briefing
October 29, 2026
(688180)"Shanghai Junshi Biosciences Co., Ltd."Announcement on Voluntary Disclosure of the Grant of Regular Approval by the National Medical Products Administration for Toripalimab for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma After Failure of Platinum-based Chemotherapy
October 28, 2026
(688180)"Shanghai Junshi Biosciences Co., Ltd."Announcement on Voluntary Disclosure of the Acceptance of the Marketing Application for Toripalimab Injection (Subcutaneous Injection) for a New Indication in First-line Treatment of HER2-Expressing Urothelial Carcinoma
October 28, 2026
Junshi Biosciences Announces the Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS207 in Combination with JS007 for the First-Line Treatment of Advanced Hepatocellular Carcinoma
October 29, 2026
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
October 28, 2026
Junshi Biosciences Announces Final Analysis Results of the Phase 3 NEOTORCH Study at ESMO Congress 2026
October 27, 2026
(688180)"Shanghai Junshi Biosciences Co., Ltd."Announcement on Voluntary Disclosure of Completion of First Patient Dosing in the Phase III Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma
October 23, 2026
Announcement on Satisfaction of Exercise Conditions for the 1st Exercise Period of the Initial Grant under the 2025 A-Share Stock Option Incentive Plan and Cancellation of Certain Stock Options
September 23, 2026
Announcement on Convening the 2026 Semi-annual Performance Briefing
September 4, 2026
Announcement on Shareholding Reduction Plan of Shareholder
August 30, 2026
Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates
August 26, 2026
Announcement on Results of Issuance of the 3rd Tranche of Sci-Tech Innovation Bonds in 2026
August 21, 2026
Announcement on Results of Shareholding Reduction by Shareholder
August 19, 2026
Indicative Announcement on Change in Equity of Shareholders Holding More Than 5% of the Shares Reaching 1% Threshold
August 10, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
July 27, 2026
Announcement on Results of Issuance of the Second Tranche of Sci-Tech Innovation Bonds in 2026
July 22, 2026
Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC
July 21, 2026
Notice on Convening the 1st Extraordinary General Meeting in 2026
July 8, 2026
Announcement on Signing of an Authorization and License Agreement with Fosun Wanbang
July 1, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
June 26, 2026
Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale
June 15, 2026
Notice on Convening the 2025 Annual General Meeting
June 5, 2026
Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC
May 26, 2026
Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report
May 22, 2026
Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma
May 21, 2026
Announcement on Resolutions of the 19th Meeting of the 4th Board of Directors
April 27, 2026
Announcement on Shareholding Reduction Plan of Shareholders
April 23, 2026
Announcement on Increasing Implementation Subject of Sub-Projects of Some Investment Projects Financed by Raised Funds
April 21, 2026
Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026
April 20, 2026
Announcement on Expiration of Shareholding Reduction Plan for Shareholders with Over 5% Shares and Non-Execution of Shareholding Reduction
April 10, 2026
Announcement on Result of Share Increase by the Controlling Shareholder and Actual Controller & Chairman, and the Equity Change Reaching the 1% Scale
March 31, 2026
Announcement on Convening the 2025 Annual Performance Briefing
March 20, 2026
Announcement on Voluntary Disclosure of Progress in Shareholding Increase for Controlling Shareholder, One of Actual Controllers and Chairman
March 16, 2026
Junshi Biosciences Announces 2025 Full Year Financial Results and Provides Corporate Updates
March 13, 2026
Announcement on Return of Idle Raised Funds Temporarily Used to Supplement Current Capital
March 12, 2026
Announcement on Progress in Shareholding Increase for Controlling Shareholder, One of Actual Controllers and Chairman
March 10, 2026
Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications
March 9, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 27, 2026
Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor)
February 24, 2026
Earnings Preannouncement for 2025
January 30, 2026
Announcement on the Results of Issuance of the 2026 Phase I Science and Technology Innovation Bonds
January 26, 2026
Announcement on Postponing Investment Projects Financed by Raised Funds
December 29, 2025
Announcement on Receipt of the "Notice of Registration Acceptance" from the National Association of Financial Market Institutional Investors
December 25, 2025
Announcement on Shareholding Reduction Plan for Shareholders with Over 5% Shares
December 18, 2025
Announcement on Voluntary Disclosure of the FDA Approval of Clinical Trial Application for JS212
December 14, 2025
Announcement on Voluntary Disclosure of New Indication of Tuoyi® and the Inclusion of Junshida® in the National Medical Insurance Catalog
December 7, 2025
Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis
December 5, 2025